![]() |
市場調查報告書
商品編碼
1476375
到 2030 年合法大麻市場預測:按產品類型、化合物、交付模式、種類、分銷管道、應用、最終用戶和地區進行的全球分析Legal Marijuana Market Forecasts to 2030 - Global Analysis By Product Type (Tinctures, Flower Buds, Oils, Topicals and Other Product Types), Compound, Mode of Delivery, Species, Distribution Channel, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球合法大麻市場規模將達到 210 億美元,預計到 2030 年將達到 1,162 億美元,預測期內複合年成長率為 27.7%。
大麻是乾燥的大麻植物部分的乾燥混合物,顏色為綠色、棕色或灰色。這種植物被廣泛用作治療各種疾病的娛樂藥物。在許多國家,出於娛樂和醫療目的種植、擁有和分銷大麻是合法的。大麻自古以來就被用於藥用,但它並不是治療的首選藥物。由於對其潛在醫療用途的研究,大麻目前用於許多適應症。
2023 年《Jama Network Open》上發表的一項研究發現,超過一半的成年人(1,661 人中有 948 人)使用大麻來治療慢性疼痛。
擴大醫療環境的接受度
由於人們越來越認知到大麻的治療潛力,大麻市場的醫療接受度正在顯著上升。正在進行的研究正在揭示大麻化合物的藥用特性,越來越多的醫療專業人員正在接受其用於治療各種疾病,包括慢性疼痛、癲癇和焦慮。這種日益成長的接受度正在推動思維方式的改變,導致合法化的擴大和針對患者需求的新醫用大麻產品的發展。
嚴格的法規和法律障礙
醫用大麻市場面臨嚴格的監管和眾多的法律障礙,為企業和消費者帶來了重大挑戰。這些障礙包括許可證要求、稅務複雜性、聯邦銀行限制、遵守各種州法規以及嚴格的產品測試標準。此外,該行業還面臨供應鏈物流、行銷法規和持續的立法變革等問題,為相關人員創造了一個複雜的環境。
創新和產品開發
公司正在投資研究,以創造新的菌株、食品和飲料等注入產品,以及電子煙和外用藥等先進的輸送方法。這種動態情況正在推動種植者、製造商和科技公司之間的合作,以創造更安全、更有效、劑量更精確的大麻產品,以滿足不斷變化的市場需求。
公共衛生問題
大麻市場引起了公眾對濫用可能性的擔憂,特別是在弱勢群體中。問題包括過量攝取導致駕駛和認知功能受損、成癮風險以及對產品品質和效力的監管不足。此外,人們也擔心二手菸暴露和頻繁吸食大麻對健康的長期影響。因此,這些都是阻礙市場成長的因素。
COVID-19 大流行對合法大麻市場產生了多種影響。一方面,它刺激了尋求緩解壓力和替代醫學的人們的需求增加。結果,我們在一些地區實現了創紀錄的銷售額。另一方面,供應鏈中斷、藥局暫時關閉和經濟不確定性成為問題。也實施了監管改革,包括允許路邊取貨和送貨。總體而言,市場表現出韌性,但由於疫情的不可預測性而面臨營運障礙。
預計預測期內花蕾田規模最大
預計花蕾田在預測期內將是最大的。花蕾也稱為花蕾,是植物中最有效的部分,含有高濃度的大麻素。品質是決定消費者偏好的重要因素,香氣、風味和外觀等特徵會影響購買決策。種植者致力於最佳化生長條件,以生產具有不同形狀的緻密、樹脂質芽,以滿足大麻鑑賞家的不同偏好。
預計製藥業在預測期內複合年成長率最高
預計製藥業在預測期內複合年成長率最高。公司正在探索大麻素對各種醫療狀況的治療潛力。從疼痛管理到神經系統疾病,藥物正在探索各種應用,以滿足監管標準並創造滿足患者需求的創新治療方法。藥物和合法大麻的這種交叉是醫療保健創新的一個有前途的前沿。
在態度轉變和監管變化的推動下,預計北美在預測期內將佔據最大的市場佔有率。這種成長催生了各種各樣的產品,從傳統花卉到食用品、濃縮物和外用藥。合法化使消費者可以獲得各種各樣的大麻產品。該市場吸引了大量投資、創造就業機會並產生稅收。
預計亞太地區在預測期內複合年成長率最高。在該地區大多數國家,娛樂性使用大麻仍然普遍違法。然而,有一些關於出於休閒目的將其合法化或合法化的可能性的運動和討論。希望利用新興合法大麻市場的投資者和公司對該地區的興趣日益濃厚。這不僅包括種植和分銷,還包括大麻藥物的研究和開發。
According to Stratistics MRC, the Global Legal Marijuana Market is accounted for $21.0 billion in 2023 and is expected to reach $116.2 billion by 2030 growing at a CAGR of 27.7% during the forecast period. Marijuana is the dry mixture of dried marijuana plant parts that is green, brown, or grey in color. This plant is widely used as a recreational drug to treat various ailments. In many nations, it is legal to grow, possess, and distribute marijuana for both recreational and medical purposes. Although it has long been used medicinally, cannabis is not the first choice for treatment. Cannabis is now used for a number of indications as a result of research into its potential medical uses.
According to a study published in Jama Network Open in 2023, more than half of adults (948 out of 1661) used cannabis to manage their chronic pain.
Rising medical acceptance
The market is experiencing a notable rise in medical acceptance due to growing recognition of its therapeutic potential. With ongoing research revealing the medicinal benefits of cannabis compounds, more medical professionals are embracing its use for various conditions like chronic pain, epilepsy, and anxiety. This increasing acceptance is fostering a shift in attitudes, leading to expanded legalization and the development of new medical cannabis products tailored to meet patients' needs.
Strict regulations and legal hurdles
The market faces strict regulations and numerous legal hurdles, posing significant challenges to businesses and consumers alike. These barriers include licensing requirements, taxation complexities, banking limitations due to federal laws, compliance with varying state regulations, and stringent product testing standards. Additionally, the industry contends with issues such as supply chain logistics, marketing restrictions, and ongoing changes in legislation, making it a complex landscape for stakeholders to navigate and thrive within.
Innovation and product development
Companies are investing in research to create novel strains, infused products like edibles and beverages, and advanced delivery methods such as vaping and topicals. This dynamic landscape encourages collaborations between growers, manufacturers, and tech companies, leading to the creation of safer, more potent, and precisely dosed cannabis products that cater to evolving market demands.
Public health concerns
The market raises public health concerns regarding potential misuse, especially among vulnerable populations. Issues include overconsumption leading to impaired driving or cognitive function, addiction risks, and inadequate regulation of product quality and potency. Additionally, there are concerns about second-hand smoke exposure and the long-term health effects of frequent marijuana use. Therefore, these are the factors hampering the growth of the market.
The COVID-19 pandemic has had a mixed impact on the legal marijuana market. On one hand, it spurred increased demand as people sought stress relief and alternative medical treatments. This led to record sales in some regions. Conversely, supply chain disruptions, temporary dispensary closures, and economic uncertainty posed challenges. Regulatory changes, such as allowing curbside pickup and delivery, were also implemented. Overall, the market demonstrated resilience but faced operational hurdles due to the pandemic's unpredictability.
The flower buds segment is expected to be the largest during the forecast period
The flower buds segment is expected to be the largest during the forecast period. These buds, also known as nugs, are the most potent part of the plant, containing high concentrations of cannabinoids. Their quality is a key factor in consumer preferences, with characteristics like aroma, flavor, and appearance influencing purchasing decisions. Cultivators focus on optimizing growth conditions to produce dense, resinous buds with diverse profiles to cater to the varied tastes of cannabis enthusiasts.
The pharmaceutical segment is expected to have the highest CAGR during the forecast period
The pharmaceutical segment is expected to have the highest CAGR during the forecast period. Companies are exploring the therapeutic potential of cannabinoids for various medical conditions. From pain management to neurological disorders, pharmaceuticals are exploring various applications, aiming to create innovative treatments that meet regulatory standards and address patients' needs. This intersection of pharmaceuticals and legal marijuana represents a promising frontier in healthcare innovation.
North America is projected to hold the largest market share during the forecast period propelled by shifting attitudes and regulatory changes. This growth has led to a diverse range of products, from traditional flower to edibles, concentrates, and topical. Legalization has led to a wide range of cannabis products being available to consumers. The market has attracted substantial investment, creating jobs and generating tax revenue.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The recreational use of marijuana is generally still illegal in most countries in the region. However, there are movements and discussions in some places about potential decriminalization or legalization for recreational purposes. There is a growing interest from investors and businesses in the region to capitalize on the emerging legal marijuana market. This includes not only cultivation and distribution but also research and development of cannabis-based pharmaceuticals.
Key players in the market
Some of the key players in Legal Marijuana market include Green Roads, VIVO Cannabis Inc., Organigram Holding, Inc., Dr. Hemp Me., Gaia Herbs Farm, Royal CBD, Canopy Growth Corporation, Hemp Production Services, CV Sciences, Inc. , Aphria, Inc., Isodiol International Inc, The Cronos Group, Medical Marijuana, Inc. , Aurora Cannabis and GW Pharmaceuticals, plc.
In January 2024, Village Farms International, Inc., announced the launch of two cannabis brands in the UK, such as Pure Sunfarms and The Original Fraser Valley Weed Co. (Fraser Valley). 4C LABS, a UK-based medical cannabis company, will distribute these brands.
In March 2023, Canopy Growth introduced six new beverage flavors. Under the Deep Space brand, the company announced Canada's first cannabis-infused beverage with naturally occurring caffeine.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.